GlassScriptPhysician profile
Michelle Stroup
NPI 1174155683
$3,222.70
in general payments reported to CMS, 2019-2025
26 companies · $765 in 2025
The $765 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $158 · 2022: $424 · 2023: $838 · 2024: $1,038 · 2025: $765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,609 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,609.31 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $849.36 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $481.76 | 2021-2025 | |
| Lilly USA, LLC | $401.16 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $270.34 | 2022-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $260.73 | 2022-2025 | Airsupra, Farxiga, Lokelma |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $162.76 | 2025 | Caplyta |
| Pfizer INC. | $126.19 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $104.81 | 2023-2024 | Rexulti |
| Exact Sciences Corporation | $88.11 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $66.30 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $51.22 | 2024-2025 | Auvelity |
| Ultragenyx Pharmaceutical INC. | $37.92 | 2022-2023 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.66 | 2021 | |
| Medtronic, INC. | $32.87 | 2023 | Intellis Adaptivestim |
| Antares Pharma, INC. | $30.96 | 2022-2023 | Tlando, Nocdurna, Xyosted |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $30.66 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.68 | 2022 | |
| Eisai INC. | $22.97 | 2024 | |
| Gilead Sciences, INC. | $22.89 | 2025 | |
| Photonicare INC | $22.60 | 2025 | Otosight Middle Ear Scope |
| Xeris Pharmaceuticals, INC. | $21.11 | 2023 | Keveyis |
| Genentech USA, INC. | $18.73 | 2021 | |
| Sumitomo Pharma America, INC. | $18.06 | 2024 | Gemtesa |
| Currax Pharmaceuticals LLC | $17.52 | 2023 | Contrave |
| Astellas Pharma US INC | $14.43 | 2024 | Veozah |
| Glaxosmithkline, LLC. | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Stroup listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.